KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Vebreltinib for Previously Treated Astrocytoma, IDH-Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with PTPRZ1-MET Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Trial.

Zhaoshi Bao, Yake Xue, Yanhui Liu, Shouwei Li, Liang Wang, Yan Qu, Yonggao Mou, Rutong Yu, Jinsong Wu, Yu Yao, Kai Shu, Guangyuan Hu, Linbo Cai, Wenbin Li, Xiaoguang Qiu, Yunqian Li, Lei Zhang, Songtao Qi, Ying Ji, Chunxiao Ma, Wenbin Ma, Gang Li, Rongjie Tao, Chongran Sun, Ligang Chen, Sheng-Qing Lv, Peng Liang, Hao Pan, Woo Yat Ming Peter, Chan Tat Ming Danny, Qing Mao, Xinting Wei, Tao Jiang

Cancer Commun (Lond) 46 0019

PMID41821581
PMCIDPMC12976379
DOI10.34133/cancomm.0019
发表日期2026-03-13
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Background: High-grade gliomas, including isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH wild-type glioblastoma, have a poor prognosis and limited treatment options. The PTPRZ1-MET (ZM) fusion gene is a potential therapeutic target. This study evaluated vebreltinib, a highly selective, adenosine-triphosphate-competitive inhibitor of the mesenchymal-epithelial transition factor (MET), in patients with ZM-fusion-positive glioma. Methods: In this multicenter, open-label ZM FUsion GENe (FUGEN) trial, patients with previously treated astrocytoma, IDH-mutant, grade 4, or glioblastoma, IDH wild-type, harboring the ZM fusion were randomized in a 1:1 ratio to receive vebreltinib (300 mg orally twice daily) or control treatment (temozolomide or cisplatin plus etoposide) in 28-d cycles. The primary end point was overall survival (OS). Key secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety analyses. Results: Eighty-one patients (42 in the vebreltinib group and 39 in the control group) were included in the full analysis set. As of 2023 April 1, the median follow-up duration was 5.9 (range, 0.8 to 44.7) months in the vebreltinib group and 3.4 (range, 0.5 to 40.5) months in the control group. Median OS was significantly longer in the vebreltinib group than in the control group (6.3 months versus 3.4 months; hazard ratio [HR], 0.52; 95% confidence interval [CI], 0.32 to 0.85; stratified log-rank P = 0.007). In the IDH-mutant subgroup, median OS was 7.7 months in the vebreltinib group and 3.3 months in the control group (HR, 0.48; 95% CI, 0.28 to 0.80; stratified log-rank P = 0.005). Among patients with a baseline tumor diameter of ≤3.0 cm, median OS was 32.5 months in the vebreltinib group versus 4.2 months in the control group (HR, 0.27; 95% CI, 0.07 to 1.06; stratified log-rank P = 0.046). Median PFS was also longer in the vebreltinib group (1.9 months versus 1.1 months; HR, 0.54; 95% CI, 0.33 to 0.88; stratified log-rank P = 0.012). The ORR was 9.5% with vebreltinib and 2.6% with control treatment. The incidence of grade ≥3 adverse events was comparable between groups, and no treatment-related deaths were reported. Conclusion: Vebreltinib significantly improved OS in patients with previously treated high-grade glioma harboring the ZM fusion, particularly in the subgroup with IDH-mutant astrocytoma, and the safety profile was manageable. Trial registration: This study was registered with the Chinese Drug Clinical Trial Registry (ChinaDrugTrials.org.cn) under the identifier, CTR20181664 (registration date: 2018 September 19).

KM 提取结果

2 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 2.

Fig. 2. Kaplan–Meier curves in the full analysis set ( n = 81). (A) Overall survival (OS). (B) Progression-free survival (PFS). HR, hazard ratio; CI, confidence interval; n .censor, number of censoring.

A

Overall survival

Fig. 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Progression-free survival

Fig. 2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

Fig. 3.

Fig. 3. Subgroup analysis of overall survival. (A) Kaplan–Meier estimates of OS in patients with a maximum lesion diameter at baseline of ≤3.0 cm. (B) Forest plot of OS across subgroups. HR, hazard ratio; CI, confidence interval; NE, not estimatable; n.censor, number of censoring; KPS, Karnofsky Performance Status; IDH, isocitrate dehydrogenase; max, maximum; MGMT, O 6 -methylguanine-DNA methyltransferase. Asterisk (*) indicates that concomitant antitumor therapy refers to antitumor treatment with nonstudy drugs administered during the survival follow-up period. Note that 4.285 cm was the median baseline value of maximum lesion diameter.

A

OS

Fig. 3. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 2:extreme jump曲线 2:extreme upward reversal
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1.Fig. 1. Flowchart of patient screening and randomization. In the vebreltinib group, the reported discontinuations due to AEs included cases triggered by symptomatic worsening. Subsequent blinded independent radiographic review determined that 5 of the 8 patients who discontinued treatment for this reason had concurrent disease progression. FAS included all patients who met the following criteria: (a) histologically confirmed astrocytoma, IDH -mutant, grade 4, or glioblastoma, IDH wild-type; (b) molecular confirmation of a ZM fusion gene; (c) recurrent disease following prior radiotherapy and temozolomide, or ineligibility for radiotherapy, or intolerance to temozolomide; and (d) receipt of at least one dose of the study drug with at least one postbaseline assessment. ITT population included all randomized patients. SS included all patients who received at least one dose of the assigned treatment and had available posttreatment safety data. SS, safety set; ITT, intention-to-treat; FAS, full analysis set.
非 KM Figure